MDxHealth (NASDAQ:MDXH) Issues Earnings Results

MDxHealth (NASDAQ:MDXH) issued its quarterly earnings results on Wednesday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.07, Zacks reports. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%.

MDxHealth Stock Down 6.2 %

MDXH stock traded down $0.12 during trading on Wednesday, reaching $1.83. 97,593 shares of the company traded hands, compared to its average volume of 103,033. The company has a market capitalization of $86.54 million, a price-to-earnings ratio of -1.20 and a beta of 1.34. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54. The business has a 50 day simple moving average of $2.02 and a 200 day simple moving average of $2.20. MDxHealth has a 12 month low of $1.55 and a 12 month high of $3.85.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MDXH. Lake Street Capital initiated coverage on shares of MDxHealth in a research note on Thursday, October 31st. They set a “buy” rating and a $7.00 target price on the stock. Piper Sandler lowered their price objective on MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.